Alfuzosin for the management of benign prostate hyperplasia

David M. Weiner, Franklin C. Lowe

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Alfuzosin (UroXatral®, Sanofi-Synthelabo) a quinazoline derivative, has well-documented α1-adrenoreceptor antagonist activity. These receptors are present in the smooth muscle located at the bladder base, proximal urethra, prostate and prostatic capsule as well as in vascular and nervous systems. Consequently, alfuzosin has the ability to reduce the tone of these areas, effectively decreasing bladder outlet resistance. A sustained-release formulation of alfuzosin is currently available in Europe and is FDA-approved in the US. The confirmed efficacy, proven bioavailability and good cardiovascular safety profile support the use of this drug for the management of lower urinary tract symptoms secondary to benign prostate hyperplasia (BPH). These findings have been confirmed in a large cohort of patients treated in general practice. Additionally, treatment with alfuzosin has demonstrated a favourable impact on quality of life of patients with BPH.

Original languageEnglish (US)
Pages (from-to)2057-2063
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Issue number11
StatePublished - Nov 2003
Externally publishedYes


  • Alfuzosin
  • Benign prostate hyperplasia
  • α-antagonist

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Alfuzosin for the management of benign prostate hyperplasia'. Together they form a unique fingerprint.

Cite this